Ipsen S.A. (LON:0MH6)

London flag London · Delayed Price · Currency is GBP · Price in EUR
114.46
+0.66 (0.58%)
At close: Oct 17, 2025
0.58%
Market Cap8.19B
Revenue (ttm)3.22B
Net Income (ttm)383.94M
Shares Outn/a
EPS (ttm)4.60
PE Ratio21.33
Forward PE10.33
Dividend1.18 (1.03%)
Ex-Dividend DateJun 4, 2025
Volume20
Average Volume70,486
Open113.60
Previous Close113.80
Day's Range113.40 - 114.46
52-Week Range88.05 - 125.35
Beta0.20
RSI47.24
Earnings DateOct 23, 2025

About Ipsen

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t... [Read more]

Industry Pharmaceutical Preparations
Founded 1929
Employees 5,358
Stock Exchange London Stock Exchange
Ticker Symbol 0MH6
Full Company Profile

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.